Search results:
Search results from www.aesgp.eu
| Ingredient | ATC Level 1 | ATC Level 2 | Year Of Switch | Country | Status | Additional Information |
|---|---|---|---|---|---|---|
| Ibuprofen (oral) | M Musculo-skeletal system. Musculo-skeletal system | M01. Antiinflammatory and antirheumatic products | 1985 | New Zealand | OTC | Oral solids maximum 200mg/dose. 25 units now General Sale. |
| Aciclovir (topical) | D Dermatologicals. Dermatologicals | D06. Antibiotics and chemotherapeutics for dermatological use | 1992 | New Zealand | OTC | Available on general sale maximum 5%, 10g tube. |
| Cimetidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 1994 | New Zealand | OTC | — |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2005 | New Zealand | OTC | Pharmacist only. Consumer advertising permitted. |
| Levonorgestrel | G Genito urinary system and sex hormones. Genito urinary system and sex hormones | G03. Sex hormones and modulators of the genital system | 2007 | New Zealand | OTC | Emergency contraception containing levonorgestrel is pharmacist only or accredited nurses. Both the 0.75mg and the 1.5mg tablets have had non-prescription status since August 2007. From January 2016, levonorgestrel in combined oral contraceptives is available without prescription when in the manufacturer's original pack containing not more than six months supply, and when sold by a registered pharmacist who has successfully completed a training programme for oral contraception in women who have previously been prescribed an oral contraceptive within the last three years. Desogestrel, ethinylestradiol and norethisterone can also now be sold OTC. |
| Zolmitriptan | N Nervous system. Nervous system | N02. Analgesics | 2009 | New Zealand | OTC | Zolmitriptan nasal spray was switched in 2009 from prescription to pharmacist-only status in a pre-filled nasal spray device delivering not more than (two times) 5 milligrams of zolmitriptan for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms and when sold in a single-dose pack approved by the Minister or the Director-General for distribution as a restricted medicine. |
| Pantoprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2009 | New Zealand | OTC | Pantoprazole was switched in 2009 from prescription-only to S3 pharmacist-only status in tablets or capsules containing 20 milligrams or less of pantoprazole when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine. |
| Fexofenadine | R Respiratory system. Respiratory system | R06. Antihistamines for systemic use | 2010 | New Zealand | OTC | Fexofenadine was approved for distribution as a general sale medicine in 2010 in capsules containing 60mg or less of fexofenadine hydrochloride or in tablets containing 120mg or less of fexofenadine hydrochloride when sold in a pack approved by the Minister or the Director-General. Higher dosages are pharmacy-only medicines. |
| Rizatriptan | N Nervous system. Nervous system | N02. Analgesics | 2010 | New Zealand | OTC | Rizatriptan for oral use was switched from prescription to pharmacist-only status in July 2010 in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when in wafers containing 5mg or less per wafer and when sold in a pack containing not more than 2 wafers approved by the Minister or the Director-General for distribution as a restricted medicine. Otherwise prescription. |
| Omeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2010 | New Zealand | OTC | In November 2010 omeprazole, in tablets containing 20mg or less of omeprazole, with a maximum daily dose of 20mg of omeprazole in a pack size of up to 14 dosage units, was reclassified from 'restricted medicine' to 'pharmacy-only medicine' for the short-term, symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine. Medsafe should update the New Zealand Regulatory Guide-lines to reflect this recommendation and ensure that the warnings statements for omeprazole read "consult a pharmacist or doctor". |
| Lansoprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2010 | New Zealand | OTC | Lansoprazole was switched from prescription to pharmacist-only status in 2010, in tablets or capsules containing 15 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine. |
| Chloramphenicol | S Sensory organs. Sensory organs | S03. Ophthalmological and otological preparations | 2010 | New Zealand | OTC | Chloramphenicol for ophthalmic use was switched from prescription to pharmacist-only status in May 2010, except when sold in practice by a registered optometrist. |
| Famciclovir | D Dermatologicals. Dermatologicals | D06. Antibiotics and chemotherapeutics for dermatological use | 2010 | New Zealand | OTC | Famciclovir was switched from prescription to pharmacist-only status in May 2010 in tablets containing 500 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine. |
| Calcipotriol | D Dermatologicals. Dermatologicals | D05. Antipsoriatics | 2010 | New Zealand | OTC | Calcipotriol for topical use was switched from prescription to pharmacist-only status in July 2010 in medicines containing not more than 50 micrograms per gram or per millilitre and when sold in a pack of not more than 30 grams or 30 millilitres by a pharmacist to an adult with mild to moderate psoriasis previously diagnosed by a doctor. |
| Bisacodyl | A Alimentary tract and metabolism. Alimentary tract and metabolism | A06. Laxatives | — | New Zealand | OTC | — |
| Nizatidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | OTC | — |
| Aluminium hydroxide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | OTC | General sale. |
| Propantheline | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | New Zealand | OTC | — |
| Famotidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | OTC | — |
| Hexetidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A01. Stomatological preparations | — | New Zealand | OTC | External use. |
| Croconazole | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | New Zealand | N.R. | Not registered or not marketed. |
| Hyoscine butylbromide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | New Zealand | OTC | — |
| Mebeverine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | New Zealand | Rx | — |
| Metoclopramide | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | New Zealand | OTC | Pharmacist only medicines in combination with paracetamol for treatment of nausea associated with migraine. |
| Simvastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | New Zealand | Rx | — |
| Dimenhydrinate (diphenhydramine and 8-chlorotheophylline) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A04. Antiemetics and antinauseants | — | New Zealand | OTC | Pharmacy-only for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults or children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft. Pharmacist-only for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule. |
| Hyoscine (Scopolamine) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A04. Antiemetics and antinauseants | — | New Zealand | OTC | — |
| Hymecromone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A05. Bile and liver therapy | — | New Zealand | N.R. | Not registered or not marketed. |
| Domperidone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | New Zealand | Rx | — |
| Lactitol | A Alimentary tract and metabolism. Alimentary tract and metabolism | A06. Laxatives | — | New Zealand | N.R. | Not registered or not marketed. |
| Dimeticone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | New Zealand | OTC | — |
| Dicyclomine (Dicycloverine) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A03. Drugs for functional gastrointestinal disorders | — | New Zealand | Rx | — |
| Cetraxate | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | N.R. | Not registered or not marketed. |
| Fluoride (sodium) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A01. Stomatological preparations | — | New Zealand | OTC | — |
| Tranexamic acid | B Blood and blood forming organs. Blood and blood forming organs | B02. Antihemorrhagics | — | New Zealand | Rx | — |
| Selenium | A Alimentary tract and metabolism. Alimentary tract and metabolism | A12. Mineral supplements | — | New Zealand | OTC | — |
| Sucralfate | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | OTC | — |
| Vitamin A (Retinol) | A Alimentary tract and metabolism. Alimentary tract and metabolism | A11. Vitamins | — | New Zealand | OTC | — |
| Adenosine | C Cardiovascular system. Cardiovascular system | C01. Cardiac therapy | — | New Zealand | Rx | — |
| Nitro-glycerine | C Cardiovascular system. Cardiovascular system | C01. Cardiac therapy | — | New Zealand | OTC | Pharmacist only medicine for oral, sublingual or rectal use. |
| Ubidecarenone | C Cardiovascular system. Cardiovascular system | C01. Cardiac therapy | — | New Zealand | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | New Zealand | N.R. | Not registered or not marketed. |
| Ranitidine | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | OTC | — |
| Amorolfine (topical) | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | New Zealand | OTC | March 1999, S4 to S3 switch in topical preparations containing 5% or less for the treatment of onychomycoses. March 2000, all amorolfine preparations for topical use switched from S4 to S3, except for preparations containing 0.25% or less (S4 to S2). September 2006, S2 to GSL switch for preparations for treatment of tinea pedis. |
| Bifonazole | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | New Zealand | OTC | Extended to General Sale for tinea pedis only (July 1999). |
| Butenafine | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | New Zealand | N.R. | Not registered or not marketed. |
| Ciclopirox Olamine | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | New Zealand | OTC | Extended to General Sale for tinea pedis only (July 1999). |
| Levocetirizine | R Respiratory system. Respiratory system | R06. Antihistamines for systemic use | — | New Zealand | OTC | For oral use. |
| Fluconazole | D Dermatologicals. Dermatologicals | D01. Antifungals for dermatological use | — | New Zealand | OTC | Pharmacist-only for 150mg or less as a single dose for the treatment of vaginal candidiasis. |
| Carbenoxolone | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | OTC | General sale. External use only. |
- Page 1 of 6
- Next
- 50 of 263 ingredients